Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma has applied for FDA Orphan Drug Designation for Namodenoson, their treatment candidate for pancreatic cancer, highlighting a significant step in addressing this high unmet medical need. The company is poised to commence a Phase IIa clinical trial to evaluate the drug’s safety and efficacy. Namodenoson has already shown a strong safety profile in previous clinical studies and has been granted Orphan Drug Status for advanced liver cancer, suggesting potential benefits for Can-Fite upon approval.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
